The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| KLRS | -57.07% | -99.2% | -61.91% | -52% |
| S&P | +13.19% | +87.83% | +13.42% | +19% |
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Lexington, MA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $108.10M | 15.8% |
| Market Cap / Employee | $18.02M | 0.0% |
| Employees | 6 | -94.6% |
| Net Income | -$11.89M | -188.3% |
| EBITDA | -$12.74M | -126.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $42.39M | -63.7% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.17M | 0.0% |
| Short Term Debt | $0.38M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -50.77% | 3.3% |
| Return On Invested Capital | -64.89% | -6.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$11.52M | -36.5% |
| Operating Free Cash Flow | -$11.33M | -34.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.43 | 0.36 | 0.78 | 2.04 | 164.11% |
| Price to Tangible Book Value | 9.21 | 0.36 | 0.78 | 2.04 | -88.58% |
| Enterprise Value to EBITDA | 3.57 | 6.61 | 3.14 | -2.56 | -150.58% |
| Return on Equity | -45.4% | -42.0% | -50.7% | -63.5% | 0.20% |
| Total Debt | $0.00M | $0.00M | $0.00M | $1.55M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
